| Enzo Biochem to Present at 9th Annual Needham Healthcare Conference (Business Wire) NEW YORK----Enzo Biochem, Inc. , a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies, announced today that Barry Weiner, President, and David Goldberg, Vice President, Corporate Development, will be presenting at the 9th annual Needham Healthcare Conference on Thursday, June 10th, 2010 at 3:20 PM at The New York Palace Hotel in New York, N.Y. us.rd.yahoo.com |
Vivus: Options Trade for FDA Panel Decision Stock Yid submits:On July 15th the FDA Panel will be reviewing the weight loss drug made by Vivus (VVUS). If the panel gives a positive review of the drug then the stock can jump 50%, if they give the weight loss drug a negative review then the stock can drop 50%. Basically we are talking about VVUS being eiter $5 of $15 on July 16th.Complete Story » seekingalpha.com |
No Bleeding at Haemonetics David Greene submits:Haemonetics (NYSE:HAE), the automated blood-processing systems maker and a provider of platelet disposables and software solutions, surprised analysts last week with a better than anticipated profit and a reaffirmation of the company's guidance going forward. With 12 analysts following HAE-- 6 at a Strong Buy, 2 at a Buy and 4 at a Hold rating--the prospects for upgrades are promising. Haemonetics reported a net income of $18 million, or 70 cents a share, compared with $18.1 million, or 69 cents a share, a year ago (First Quarter, 2010). Revenue increased to $163 million (up 6%) with the contribution of a 6 percent increase in platelet disposables revenue and a 95 percent increase in software solutions revenue. Consensus estimates were earnings of 72 cents a share, excluding special items, on revenue of $167.9 million, according to Thomson Reuters I/B/E/S. The company reconfirmed its 2010 adjusted earnings outlook of $3.15 to $3.25 a share, on revenue of $703.5 million to $722.9 million vs. the average analyst estimates of $3.19 a share in earnings with revenue of $711.4 million.Complete Story » seekingalpha.com |
Cell Therapeutics to Challenge FDA Decision Zacks.com submits: Recently, Cell Therapeutics Inc. (CTIC) announced that it will appeal against the decision of the US Food and Drug Administration (FDA) to deny approval to the company’s lead candidate, pixantrone. The candidate is being developed for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who have not responded to other treatment options.In April 2010, the FDA denied approval to pixantrone, and issued a complete response letter (CRL) based on issues related to the study design. The FDA asked Cell Therapeutics to conduct an additional trial to determine the safety and efficacy of pixantrone.Complete Story » seekingalpha.com |
Cardiovascular risk reduction for diabetics? - Video ACCORD Lipid Study brings new hope to people with type 2 diabetes and atherogenic dyslipidemia says international academic foundation feedproxy.google.com |